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Abstract
Objective
Dysregulation of the Hedgehog (Hh) pathway has been described in a variety of cancers,
including cervical cancer, a disease which shares a common aetiology with vulval squa-
mous cell carcinoma (VSCC). Here, we investigate a large number of primary VSCC cases
for evidence of Hedgehog pathway activation and examine the implications of pathway
activity on clinical outcomes in a cohort of patients with primary VSCC.
Methods
Archival histology blocks containing VSCC and histologically normal adjacent epithelium
were retrieved from a cohort of 91 patients who underwent treatment for primary VSCC.
Immunohistochemistry staining was undertaken to assess for the expression of key Hh
pathway components (SHH, PTCH1, GLI1). A competing risks statistical model was used to
evaluate the implications of the levels of key Hh pathway components on clinical outcomes.
Results
We show that 92% of primary VSCC cases over-expressed one or more components of the
Hh signalling pathway when compared to the adjacent normal epithelium. While expression
of SHH and GLI1 did not correlate with any clinicopathological criteria, over- or under-
expression of PTCH1 was associated with a reduced or increased risk of developing a local
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disease recurrence, respectively. In VSCC arising on a background of Lichen Sclerosus, the
risk of local recurrence was potentiated in cases where PTCH1 was under-expressed.
Conclusions
Our findings reveal, for the first time, that the Hh pathway is activated in VSCC and that
PTCH1 expression can be used as a biomarker to stratify patients and inform clinicians of
the risk of their local recurrence, particularly in cases of VSCC associated with LS.
Introduction
Vulval cancer comprises 6% of all gynaecological malignancies in the UK, with squamous cell
carcinoma (VSCC) making up 90% of all cases [1]. It is predominantly a disease of the elderly,
with three-quarters of cases affecting those aged over 60 years, making radical treatment chal-
lenging due to specific age-related comorbidities. Surgery remains the most effective treatment
modality for VSCC, and the current surgical paradigm aims to excise at least 1.5cm of tumour-
free skin along with the primary tumour to avoid local recurrence [2]. However, recently pub-
lished studies, including ours, have shown that inadequate surgical margins are not associated
with the development of local vulval recurrence (LVR) as long as the tumour is entirely excised
[3,4]. In our previous study, we found that most local recurrences occurred in cases where
optimal surgical margins had been achieved. Furthermore, we also demonstrated that VSCC
arising in a background of Lichen Sclerosus (LS), a chronic inflammatory dermatosis affecting
the whole vulva, were more likely to develop an LVR after primary treatment [5]. Our findings,
together with others, suggest that these “recurrent tumours” most likely constitute a new pri-
mary tumour that arises in a field of a molecularly altered epithelium. While the molecular
pathways linked to disease recurrence are yet to be fully defined, the Hedgehog (Hh) pathway
is of particular interest in this context, given that Hh pathway dysregulation has been described
in cancers associated with highrisk human papillomavirus (HR-HPV) and chronic inflamma-
tion [6,7]; both of which are recognised independent aetiological factors for VSCC [4].
In the canonical Hh signalling cascade, binding of Sonic Hedgehog (SHH) to the Hedgehog
receptor, PTCH1, relieves its repression on Smoothened (SMO), a G-protein coupled receptor.
This results in stabilisation and nuclear translocation of the GLI proteins and pathway activa-
tion [8]. In adulthood, this cell signalling pathway is usually repressed, but its activity is main-
tained in certain stem cell populations to promote tissue renewal and regeneration.
Dysregulation of the Hh pathway has been described in a variety of cancers from multiple tis-
sue types [9]. In gynaecological cancers, as with other malignancies, aberrant Hh pathway acti-
vation is associated with poor treatment outcomes or the development of chemoresistance
[10,11,12]. To this end, we have undertaken a study to investigate the status of Hh pathway
activity in VSCC using our previously published cohort of patients diagnosed with primary
VSCC [5] and examined the possible implications of Hh pathway activation to clinicopatho-
logical criteria.
Materials and methods
Study population: This included 91 primary cases of VSCC diagnosed between 2000 and 2008
and managed in the Pan Birmingham Gynaecological Cancer Centre. Comprehensive infor-
mation of the cohort’s demography, behaviour, clinicopathological variables, HPV genotyping
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and treatment outcomes are already published [5]. Time to recurrence/death was measured
from the date of primary treatment to the date of clinical follow up where the diagnosis was
made based on either histological confirmation of invasive disease, clinically diagnosed recur-
rence, clinically unambiguous evidence of disease progression, or death. All patients were fol-
lowed up continuously for 56 months. As outlined in our previous study and having
previously observed 2 different patterns of local recurrence, we have dichotomised LVR into
local relapse (LR), a tumour which recurs within 2 cm of the primary tumour, and second field
tumour (SFT), a tumour which recurs >2 cm away from the primary tumour [5].
Immunohistochemical (IHC) staining: Archival formalin-fixed paraffin embedded (FFPE)
histology blocks consisting of the primary tumour and their corresponding histologically adja-
cent normal vulval epithelium were retrieved and 4-micron sections processed for immuno-
histochemical staining as previously described [13]. The antibodies used to stain for Hh
pathway components included antibodies specific for SHH, PTCH1 and GLI1 are listed in S1
Table. The expression of Hh pathway components was quantified using the H-score system
[13,14]; and over- or under-expression of Hh pathway components in the tumour were
defined by a H-score of�1 when compared to the respective adjacent normal epithelium. His-
tology and staining were comprehensively reviewed by a gynaecological cancer specialist
pathologist, RG.
HPV-genotyping: This was performed on formalin fixed paraffin embedded blocks of
VSCC using standard PCR methods as previously described to detect the presence of HPV16
and 18 strains [15].
Statistical analyses: Expression of Hh pathway components in tumour were compared to
that of the corresponding measurements in adjacent normal epithelium using the Wilcoxon
signed rank test for paired observations. The tumour expression of GLI1 and PTCH1 were
also correlated with SHH using linear regression. Survival time was defined as time to recur-
rence or death, with death from primary disease contributing as a recurrence, or date last
known to be alive for surviving patients. Death precludes the observation of disease recur-
rence, and hence standard survival methodology, Kaplan Meier estimates alongside Cox pro-
portional hazards modelling, yield biased risk estimators. As such, competing risk models
were derived to take into consideration that most women in our cohort were elderly and likely
to die of causes unrelated to VSCC [16]. We quantify the impact of patient, disease and treat-
ment characteristics upon incidence of recurrent disease, and quantify incidence modification
using a Sub-Hazards-Ratio (SHR) with 95% confidence interval (95% CI). Exploratory univari-
able models were constructed, followed by multivariable models with prognosticators selected
based on Akaike information criterion (AIC). For the univariable analyses, we considered pre-
dictors that were significant at the p = 0.1 to be potential incidence modifiers. The assumptions
associated with such models were tested, and time-dependent effects were explored upon indi-
cation non-proportional sub-hazards. The strict interpretation of a sub-hazard ratio is dis-
cussed later. For simplicity, we interpret a significant SHR as an association with incidence
modification. Those factors considered were: Hh pathway components (SHH, PTCH1, GLI1);
vulvar intraepithelial neoplasia (VIN); LS; age; smoking status; disease stage; disease focality;
groin node metastasis; groin node surgery; lymphovascular space invasion (LVSI); excision
margins; histology grade; chemo/radiotherapy; radiotherapy for sub-optimal surgery; type of
surgery. Further univariable analysis was also undertaken to assess cytosolic GLI1 or combined
cytosolic and nuclear GLI1 expression in tumour and adjacent normal tissue with respect to
the incidence of recurrent disease. Statistical analyses were performed using Stata V14.
Details of Ethics Approval: This study was approved by the National Research Ethics Ser-
vice Committee West Midlands–Solihull (Reference 11/WM/0070). All samples were
anonymised.
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Results
Study population
A summary of the distribution of the clinicopathological variables for all the 91 patients is
shown in Table 1. The mean age of the women in this cohort was 74 years (IQR 63–81). As
this is a retrospective cohort, all patients had surgico-pathological staging according to the
FIGO 1998 staging criteria. The staging system was simplified into early (stage 1 and 2) and
advanced stage (stage 3 and 4) to facilitate statistical analysis: 55 (60%) patients presented with
early stage disease and 36 (40%) had advanced stage disease. In 40 (44%) patients LS was
found adjacent to their main VSCC and VIN was found adjacent to the main tumour in 66
Table 1. Distribution of clinicopathological variables in the Birmingham VSCC cohort.
Variable Number of cases n (%)
Age (years) Mean 74.0 (IQR 63.0, 81.0)
Smoking status Smoker/Ex-Smoker 26 (28.6)
Never smoker 48 (52.7)
Missing 17 (18.7)
Stage (simplified) 1/2 (Early) 55 (60.4)
3/4 (Advanced) 36 (39.6)
Tumour Size < 2cm 9 (9.9)
2-<4cm 37 (40.7)
4<6cm 24 (26.4)
> = 6cm 13 (14.3)
Missing 8 (8.8)
Focality Unifocal 73 (80.2)
Multifocal 18 (19.8)
Histology grade Well 17 (18.7)
Moderate 31 (34.1)
Poorly 37 (40.7)
Not graded 6 (6.6)
LVSI Yes 38 (41.8)
No 50 (54.9)
Missing 3 (3.3)
LS, +/- VIN LS, +/- VIN 40 (44.0)
No LS 51 (56.0)
VIN uVIN, dVIN or ungraded 66 (72.5)
No VIN 25 (27.5)
HPV 16/18 E6 Positive 52 (57.1)
Negative 39 (42.9)
Groin node metastasis Yes 26 (28.6)
No 65 (71.4)
Excision Margins Optimum 48 (52.7)
Sub-optimum 33 (36.3)
Incomplete 7 (7.7)
Missing 3 (3.3)
Groin Node Surgery SNLB/GLND 70 (76.9)
No nodal surgery 21 (23.1)
Chemo/Radio-therapy Yes 28 (30.8)
No 63 (69.2)
https://doi.org/10.1371/journal.pone.0206553.t001
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(72.5%) patients. HPV genotyping revealed that 52 (57%) tumours tested positive for HPV16/
18 subtypes with the remaining 39 (43%) of the cohort testing negative.
Surgical excision was the main modality of treatment with 89 (98%) patients undergoing
radical excision to remove their primary tumour, while 70 (77%) patients had groin lymphade-
nectomies or sentinel lymph node biopsies. Of the 89 patients who had surgery, 48 (54%) had
“optimal tumour resection” with tumour free margins of at least 8mm or more; 33 (37%) had
tumour free margins of less than 8mm; tumours were incompletely excised in 7 (8%) cases;
and resection margins were unavailable for 1 patient. Primary/neo-adjuvant/adjuvant radio-
therapy with or without chemotherapy was administered in 28 patients (31%).
Hedgehog pathway components (SHH, PTCH1 and GLI1) are over-
expressed in VSCC
IHC staining was undertaken to evaluate the expression of Hh pathway components (SHH,
PTCH1 and GLI1) in the primary tumour and their respective adjacent histologically normal
epithelium. In all cases, expression of SHH ligand was localised to the cytosol; PTCH1 to the
membrane, cytosol and nucleus; and GLI1 to the cytosol and nucleus (Fig 1 and S1 Fig for
high resolution images).
Compared to adjacent histologically normal epithelium, 84 (91%) VSCC cases exhibited
over-expression of at least one Hh pathway component (SHH or GLI1 or PTCH1): SHH
ligand was over-expressed in the primary tumour in 73 (80%) cases; 47 (52%) cases showed a
cytosolic over-expression of GLI1, and PTCH1 was over-expressed in 53 (58%) cases. Paired
non-parametric comparisons of average tumour expression showed an increase in the expres-
sion of SHH ligand (p<0.001), PTCH1 (p<0.001) and cytosolic GLI1 (p = 0.002) in the pri-
mary tumour compared to the adjacent histological normal epithelium (Fig 2). Although the
average levels of nuclear GLI1 expression were higher in VSCC compared to adjacent normal
epithelial, the difference was not statistically significant (p = 0.982). There was a weak positive
correlation between the levels of SHH and its downstream targets: PTCH1 and GLI1 (subdi-
vided into cytosolic GLI1 and nuclear GLI1), with R-squared values of 9%, 11% and 4% respec-
tively. The R-squared value for the correlation between PTCH1 and GLI1 was 26%.
Increased expression of PTCH1 in VSCC is associated with a reduced risk
of developing a local disease recurrence
The median follow-up for patients who were still alive was 8.5 years, and 35 (38%) patients
within this cohort were still alive at the time this study was undertaken. Of these patients, 26
(29%) women had a total of 44 episodes of LVR: 17 (19%) had LR, and 18 (20%) had SFT. Dis-
ease-specific death (DSS) was reported in 28 (31%) women. Seven women who had residual
disease following primary intervention were omitted from the analyses of recurrence
outcomes.
The univariable analyses (Table 2) indicated that Hh pathway component expression and
clinical determinants which predispose to LVR were the presence of LS adjacent to VSCC
(SHR = 3.96 95% CI 1.55, 10.10; p = 0.004) and testing negative for HR-HPV (SHR 2.60 95%
CI 1.14, 5.92; p = 0.022). For LR, the sole determinant was the presence of adjacent LS
(SHR = 5.35 95% CI 1.50, 19.00; p = 0.010), while over-expression of PTCH1 was found to pro-
tect against LR (SHR 0.25 CI 0.080, 0.778, p = 0.0017). For DSS, the clinical determinants asso-
ciated with adverse outcomes were advanced disease stage (SHR 2.58 95% CI 1.24, 5.33;
p = 0.011) and groin node metastasis (SHR 2.96 95% CI 1.42, 6.18; p = 0.004).
Multivariable analyses, with adjustment for confounding, revealed that under-expression of
PTCH1 in VSCC was associated with an increased incidence of LR (SHR = 4.00 95% CI 1.29,
Dysregulation of the Hedgehog signalling pathway in vulvar cancer
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Fig 1. The Hedgehog pathway is aberrantly activated in VSCC compared to normal vulval epithelium. Representative immunohistochemical
staining showing differential expression of SHH ligand, PTCH1, and GLI1, in normal vulval squamous epithelium, normal tumour-adjacent vulval
epithelium (upper panels) and three primary VSCC cases (lower panels) (original magnification x200). Insets show higher magnification of the same
sections (magnification x400).
https://doi.org/10.1371/journal.pone.0206553.g001
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12.50; p = 0.017) and vice versa. As reported in our previous analysis [5], the presence of LS
adjacent to the primary VSCC remained an independent clinical determinant associated with
the development of LR. For DSS, multivariable analyses revealed no confounding, and hence
groin node metastasis remained the only clinical determinant that predicts survival, with those
patients with positive groin nodes having a poorer outcome, again, a result similar to our pre-
vious analysis.
There was no correlation between GLI1 over-expression and LVR, LR, SFT or DDS. In
addition, further analysis did not reveal any association between Hh pathway component over-
expression with HR-HPV status. As reported in our previous study, HR-HPV status neither
influenced disease recurrence nor survival.
PTCH1 under expression further potentiates the risk of LR in VSCC
arising in the background of LS
As the presence of adjacent LS and the status of PTCH1 expression are both associated with an
increased incidence for LR, we next evaluated the impact of PTCH1 expression in VSCC cases
associated with and without LS. We stratified our patients into three risk groups: 1) High-risk:
VSCC associated with LS and showing PTCH1 under-expression; 2) Moderate-risk: a tumour
Fig 2. Box & Whiskers plot showing the expression of SHH, PTCH1 and GLI1 in the main VSCC tumour and respective adjacent normal
epithelium. AN = adjacent normal epithelium, Cyt = cytosolic, Nuc = nuclear.
https://doi.org/10.1371/journal.pone.0206553.g002
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Table 2. Univariable analyses.
Local Vulva
Recurrence (LVR)
Local Relapse
(LR)
Second Field Tumour (SFT) Disease Specific
Survival (DSS)
Covariate HR (95% CI) P-
value
HR (95% CI) P-
value
HR (95% CI) P-value HR (95% CI) P-
value
SHH: Ref Cat = No over-
expression
Over-expressed 6.62 (0.96, 45.80) 0.056 3.86 (0.54,
27.86)
0.180 2.07 (0.52, 8.19) 0.302 1.59 (0.57, 4.39) 0.372
PTCH1: Ref Cat = No over-
expression
Under-expressed 0.85 (0.34, 2.13) 0.728 0.25 (0.08,
0.78)
0.017 1.16 (0.35, 3.78) 0.810 0.73 (0.32, 1.65) 0.445
Unavailable 1.18 (0.31, 4.43) 0.811 0.80 (0.18,
3.64)
0.772 0.70 (0.08, 6.20) 0.748 1.07 (0.39, 2.99) 0.892
GLI1(Nuc): Ref Cat = No
over-expression
Over-expressed 1.20 (0.51, 2.81) 0.675 1.37 (0.46,
4.10)
0.577 0.72 (0.26, 2.04) 0.540 1.12 (0.51, 2.47) 0.772
Unavailable 0.99 (0.22, 4.42) 0.988 0.86 (0.10,
7.41)
0.890 Complete Complete 0.72 (0.16, 3.15) 0.662
LS, +/- Vin: Ref Cat = No LS
LS, +/- Vin 3.96 (1.55, 10.10) 0.004 5.35 (1.50,
19.00)
0.010 2.44 (0.90, 6.59) 0.078 1.56 (0.75, 3.25) 0.231
Age (years) 1.01 (0.99, 1.03) 0.281 1.01 (0.98,
1.03)
0.617 1.01 (0.99, 1.04) 0.316 1.02 (0.99, 1.04) 0.163
Smoking status: Ref Cat = No
Smoker/Ex-Smoker 0.73 (0.29, 1.84) 0.502 1.24 (0.41,
3.73)
0.702 0.51 (0.15, 1.81) 0.300 0.71 (0.28, 1.80) 0.465
Unavailable 0.58 (0.16, 2.11) 0.407 0.74 (0.15,
3.62)
0.714 0.27 (0.03, 2.21) 0.221 1.20 (0.47, 3.09) 0.707
Stage (simplified): Ref
Cat = 1/2
3/4 1.04 (0.45, 2.38) 0.930 0.80 (0.28,
2.32)
0.679 0.88 (0.29, 2.61) 0.813 2.58 (1.24, 5.33) 0.011
Disease Multifocal: Ref
Cat = No
Yes 1.46 (0.57, 3.70) 0.431 1.54 (0.49,
4.86)
0.461 0.65 (0.14, 2.94) 0.578 0.57 (0.21, 1.59) 0.284
Groin node involvement: Ref
Cat = No
Yes 1.50 (0.64, 3.50) 0.347 1.36 (0.47,
3.95)
0.567 1.04 (0.33, 3.29) 0.947 2.96 (1.42, 6.18) 0.004
LVSI: Ref Cat = No
Yes 0.48 (0.19, 1.20) 0.118 0.39 (0.13,
1.21)
0.103 0.93 (0.32, 2.68) 0.895 0.66 (0.31, 1.40) 0.279
HPV 16/18: Ref
Cat = Positive
Negative 2.60 (1.14, 5.92) 0.022 2.20 (0.79,
6.13)
0.132 1.98 (0.70, 5.62) 0.201 1.49 (0.72, 3.09) 0.284
VIN: Ref Cat = Any VIN (u.
d, ungraded)
No VIN 1.15 (0.49, 2.71) 0.743 1.31 (0.45,
3.75)
0.620 0.71 (0.20, 2.53) 0.601 2.01 (0.95, 4.28) 0.068
(Continued)
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either arising from LS or showing PTCH1 under-expression; 3) Low-risk: tumour neither
associated with LS nor showing PTCH1 under-expression. By stratifying patients according to
the level of PTCH1 expression and association with LS, we demonstrated that following adjust-
ment for patient age, LR is further potentiated in patients in the high-risk group when com-
pared to those in the low-risk group, SHR of 21.03 (95% CI: 2.08, 212.93; p = 0.010), (Fig 3A
and 3B). Further model evaluation revealed that the relative difference in sub-hazards between
the moderate and low-risk groups was not constant, that is, a statistically significant time-
dependency was observed. This indicated that, while the risk of LR between the moderate- and
low-risk groups did not differ in the first 12 months following primary surgery, the moderate-
risk group are exposed to increased relative incidence as time progresses (S2 Table).
Discussion
Our study demonstrates for the first time, that key components of the Hh pathway are fre-
quently over-expressed in VSCC compared to the adjacent normal epithelium, implying aber-
rant activation of the pathway in VSCC. Furthermore, we found that levels of the Hh receptor,
PTCH1, could predict the relative risk of developing an LR.
In our previous study, we showed that local recurrence in VSCC is not caused by failure to
achieve adequate tumour-free surgical margins and proposed that LVR may be driven by
underlying molecular changes in residual epithelium left behind after surgery [4]. Here, we
show that the Hh signalling pathway, whose dysregulation has recently been described in cer-
vical cancer [10], is also aberrantly activated in primary VSCC. Although there are a number
of ways in which the Hh pathway can become dysregulated in cancer [9], it is unclear at this
Table 2. (Continued)
Local Vulva
Recurrence (LVR)
Local Relapse
(LR)
Second Field Tumour (SFT) Disease Specific
Survival (DSS)
Covariate HR (95% CI) P-
value
HR (95% CI) P-
value
HR (95% CI) P-value HR (95% CI) P-
value
Excision Margins: Ref
Cat = Incomplete
Optimum 1.03 (0.24, 4.35) 0.966 0.56 (0.12,
2.63)
0.460 Unable to compute as 0 cases in
“Incomplete” group
0.51 (0.12, 2.10) 0.349
Sub-optimum 0.86 (0.19, 3.82) 0.839 0.50 (0.10,
2.52)
0.398 0.82 (0.20, 3.32) 0.781
Unavailable Complete Complete 7.18 (0.62, 83.16) 0.115
Histology grade: Ref
Cat = Well
Moderate 0.51 (0.14, 1.82) 0.301 0.55 (0.14,
2.18)
0.396 0.38 (0.08, 1.77) 0.216 1.12 (0.35, 3.60) 0.844
Poorly 0.86 (0.30, 2.49) 0.782 0.46 (0.12,
1.79)
0.260 0.63 (0.18, 2.20) 0.468 2.15 (0.77, 6.04) 0.145
Not graded 1.61 (0.44, 5.94) 0.474 2.61 (0.63,
10.79)
0.187 0.63 (0.08, 5.18) 0.669 1.23 (0.26, 5.78) 0.791
Tumour Size: Ref Cat = <
2cm
2-<4cm 0.81 (0.22, 3.02) 0.756 1.05 (0.22,
4.95)
0.952 0.51 (0.13, 1.97) 0.332 0.71 (0.21, 2.36) 0.578
4-<6cm 0.62 (0.15, 2.55) 0.510 0.32 (0.05,
2.24)
0.249 0.33 (0.07, 1.63) 0.174 1.68 (0.52, 5.41) 0.388
�6cm 0.39 (0.06, 2.62) 0.334 0.32 (0.03,
3.77)
0.364 0.20 (0.02, 2.06) 0.177 1.43 (0.33, 6.14) 0.628
https://doi.org/10.1371/journal.pone.0206553.t002
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stage what mechanisms are responsible for Hh pathway activation in VSCC. In situations
where pathway dysregulation plays a direct role in epithelial carcinogenesis, over-expression
of SHH ligand, mutations in PTCH1 or SMO, can all activate the Hh pathway. In the case of
basal cell carcinoma (BCC), Hh dysregulation is driven by a mutations in the PTCH1 gene,
which blocks its ability to repress SMO [17]. Although our study did not examine VSCC
tumours for evidence of PTCH1 or SMO mutations, we speculate that overexpression of SHH
ligand most likely constitutes the mechanism for pathway activation in VSCC, given that in
cases where SHH was over-expressed, there was a corresponding upregulation of PTCH1 and
GLI1. Similar findings have been reported for cervical cancer, which shares a common aetiol-
ogy to at least half of the VSCC cases [10].
In many Hh-driven cancers, the degree of pathway activation has been shown to influence
disease outcomes, suggesting that key Hh pathway components may serve as clinically useful
biomarkers to inform clinicians about treatment responses [18]. Using our previously pub-
lished patient follow-up data, univariable and multivariable analyses were constructed to inter-
rogate the association of Hh pathway components with various clinicopathological criteria. Of
Fig 3. (A) Cumulative incidence plots showing incidence associated with PTCH1 expression and/or the presence of
adjacent LS identified through multivariable analyses for time to local relapse (LR). The incidence of LR within 5 years
following primary treatment is significantly increased in the high-risk group compared to the moderate- and low-risk
groups. High risk: LS & PTCH1 under-expression; Moderate-risk: Either LS or PTCH1 under-expression; Low-risk:
Neither LS nor PTCH1 under-expression. (B) Representative IHC staining of VSCC cases displaying (a) low, (b)
medium and (c) high levels of PTCH1.
https://doi.org/10.1371/journal.pone.0206553.g003
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the major criteria investigated, our study revealed that over-expression of PTCH1 was associ-
ated with a reduced incidence of LR, while under-expression was associated with an increased
incidence. These findings are consistent with PTCH1 functioning as a tumour suppressor
gene [18]. PTCH1 functions as a negative regulator of the Hh-signalling pathway by repressing
downstream signalling from SMO. As a direct target of the GLI transcription factors, high lev-
els of PTCH1 are linked to elevated Hh pathway activation, where PTCH1 functions in a nega-
tive feedback loop to attenuate Hh signalling. Mutations or loss of PTCH1 expression, through
epigenetic silencing, leads to constitutive activation of the pathway and expression of Hh target
genes [19]. Findings from this study suggest that the loss of PTCH1 expression on a back-
ground of chronic Hh pathway activation can promote LVR and LR, implicating a role for Hh
signalling in disease recurrence.
Interestingly, we found in our sub-analysis that PTCH1 under-expression further potenti-
ates the risks of LR in VSCC arising in a background of LS, indicating that we can further strat-
ify patients who are at risk of developing an LR, using PTCH1 as a biomarker. Our
observation also suggests that Hh pathway dysregulation may be significant in the setting of
LS, given that chronic inflammation can aberrantly active the Hh pathway [7]. As only 4–5%
of LS progress to VSCC [20], it would be interesting to establish whether Hh pathway dysregu-
lation plays a role is in those cases which progress to cancer. Those patients in the Moderate-
risk group were still at risk of developing an LR over time compared to those in the Low risk
group, suggesting that either PTCH1 under-expression or LS are independent markers associ-
ated with LR. We advocate, therefore, that these patients should be followed up more fre-
quently than patients whose tumours do not show PTCH1 under-expression or do not have
underlying LS. This observation fits with our multivariable analysis indicating that both of
these are independent risk factors but could potentiate patients’ risk of developing an LR when
both are present.
At this stage, it is unclear whether further corruption of the Hh pathway is required for
LVR and LR in VSCC. In BCC, a number of Hh pathway-dependent mechanisms have been
identified which contribute to tumour recurrence in response to treatment with SMO inhibi-
tors. While mutations in SMO are commonly observed [21, 22], others are associated with
copy number changes in SUFU or GLI2 [23]. Recently, a novel mechanism has been identified
which involves non-canonical activation of the Hedgehog pathway through a mechanism
involving serum-response factor (SRF) and megakaryoblastic leukaemia 1 (MKL1)-mediated
activation of GLI1 [24]. While interrogation of such mechanisms is beyond the scope of this
study, further studies will investigate whether these or similar mutations or pathway corrup-
tion are involved in VSCC recurrence. A major strength of our study is that we compared the
levels of individual Hh pathway components (SHH, PTCH1, and GLI1) in primary tumours
with tumour adjacent normal epithelium. Such an analysis provides a valuable internal control
for each case, thereby improving the accuracy of our study. Although our study relates to a ret-
rospective cohort with a monocentric design, much like other studies performed in rare dis-
eases, we believe that our cohort has a comprehensive clinicopathological and follow up data
that allow us to interrogate the relevance of Hh pathway expression in VSCC robustly.
Despite the clear-cut demonstration that key components of the Hh pathway were over-
expressed in VSCC, the question remains as to how Hh pathway activation contributes to dis-
ease pathogenesis. This is pertinent given that expression of GLI1 did not correlate with any
specific disease parameter. In this respect, our findings are at odds with recent studies per-
formed on cervical cancer, where over-expression of key Hh components, in particular, GLI1,
correlated with disease stage, tumour grade and lymph node involvement [10, 25, 26]. Given
the complex pathobiology of VSCC, with the disease arising from HPV-dependent and inde-
pendent routes, further studies are required to unravel the underlying mechanism(s) which
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underpin the aberrant expression of the Hedgehog pathway in VSCC, and whether pathway
inhibition offers any therapeutic benefit. As in our previous study, we found no compelling
evidence to suggest that HR-HPV status influences disease outcome in VSCC [5]. The link
between Hh pathway activation and HR-HPV remains to be elucidated. Although we found
no association between HR-HPV status and Hh pathway component expression, our study did
not interrogate the transcriptional status of the virus, which we believe is beyond the scope of
this study. An additional limitation of our study was our inability to stratify the non-neoplastic
epithelial disorders (LS, uVIN, dVIN) found adjacent to VSCC into specific groups, given that
LS and VIN were frequently found to co-exist in the same tissue specimens. As the numbers in
each sub-group were too small to provide a comparison for meaningful statistical analysis, we
have grouped all patients with LS (irrespective of the presence of uVIN/dVIN) and compared
these against the two other groups, as described in our previous study [5].
We advocate the use of competing risk analyses because patients with VSCC were elderly
and likely to die of causes unrelated to their cancer; therefore, an unrelated death is a compet-
ing event. We observed in our sub-analysis, comparing the risk of LR in patients stratified into
high-, moderate- and low-risk based on PTCH1 expression and the presence of adjacent LS,
that women in the low-risk group were more likely to die of causes other than VSCC. Never-
theless, taking into account our competing risk model, we do not believe that this is likely to
influence our overall analysis.
Conclusion
Our study shows, for the first time, that the Hh signalling pathway is aberrantly activated in a
significant proportion of VSCC, irrespective of their high-risk HPV status. We show that
PTCH1 may serve as a useful biomarker to stratify patients into different risk groups, espe-
cially those with LS, so that patient management and follow-up can be tailored accordingly to
their relative risk. Ultimately, a multicentre prospective study is required to validate the useful-
ness of PTCH1 as a biomarker for risk stratification.
Furthermore, our findings offer an opportunity for us to explore and develop novel thera-
pies which target the Hh pathway, where the effectiveness of current chemotherapy for the
treatment of VSCC remains questionable and is not tolerated by most patients. In recent years,
a number of Hh pathway inhibitors have been evaluated in clinical studies. One such drug,
Vismodegib, is licensed by the FDA for the treatment of advanced or metastatic cases of BCC,
cancer driven by PTCH1 mutations [27]. Future in vitro studies will determine whether Hh-
positive VSCC-derived cell lines respond to Hh inhibitors and whether they can be used in the
neoadjuvant or adjuvant setting alongside conventional chemotherapy.
Supporting information
S1 Fig. Higher power images from immunohistochemical staining (in Fig 1) showing
stronger expression of cytosolic SHH ligand, and both cytosolic and nuclear staining of
PTCH1 and GLI1, in cells from a primary VSCC (lower panels) compared to normal vulval
squamous epithelium (upper panels) (original magnification x400).
(TIF)
S1 Table. List of antibodies used for immunohistochemical staining.
(TIF)
S2 Table. Competing risks models for LR adjusted for (mean centred) patient age, and
detailing the time-dependency of the sub-hazard in the moderate-risks group.
(TIF)
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